<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1588">
  <stage>Registered</stage>
  <submitdate>6/06/2007</submitdate>
  <approvaldate>6/06/2007</approvaldate>
  <nctid>NCT00483782</nctid>
  <trial_identification>
    <studytitle>Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer</studytitle>
    <scientifictitle>ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CDR0000548777</secondaryid>
    <secondaryid>MREC-ICON7</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fallopian Tube Cancer</healthcondition>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Primary Peritoneal Cavity Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - bevacizumab
Treatment: drugs - carboplatin
Treatment: drugs - paclitaxel
Other interventions - questionnaire administration
Other interventions - study of socioeconomic and demographic variables
Treatment: surgery - quality-of-life assessment

Other interventions: bevacizumab


Treatment: drugs: carboplatin


Treatment: drugs: paclitaxel


Other interventions: questionnaire administration


Other interventions: study of socioeconomic and demographic variables


Treatment: surgery: quality-of-life assessment


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biological progression-free interval as measured by increasing CA 125 levels</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety as measured by NCI CTAE version 3.0</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health economics</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
             cavity cancer

               -  Newly diagnosed disease

          -  Meets 1 of the following staging criteria:

               -  High-risk stage I or IIA disease (grade 3 disease or clear cell carcinoma only)

               -  Stage IIB-IV disease (all grades and all histological types)

          -  Must have undergone initial surgery (e.g., debulking cytoreductive surgery or a biopsy
             if the patient has stage IV disease) within the past 6 weeks

               -  Patients with stage IV disease for which initial surgical debulking was not
                  appropriate are eligible provided the following criteria are met:

                    -  Stage IV disease diagnosed by histology

                    -  No planned surgery prior to disease progression, including interval
                       debulking surgery

          -  Patients with prior early-stage ovarian epithelial or fallopian tube carcinoma treated
             with surgery alone are eligible at the time of diagnosis of abdominopelvic recurrence
             provided no further interval cytoreductive therapy is planned prior to disease
             progression

          -  Synchronous primary endometrial carcinoma or a past history of primary endometrial
             carcinoma allowed provided the following criteria are met:

               -  Disease = stage IB

               -  No more than superficial myometrial invasion

               -  No lymphovascular invasion

               -  Not poorly differentiated (i.e., no grade 3, papillary serous, or clear cell
                  disease)

          -  Measurable or nonmeasurable disease

          -  No ovarian nonepithelial cancer, including malignant mixed MÃ¼llerian tumors

          -  No borderline tumors (e.g., tumors of low malignant potential)

          -  No history or clinical suspicion of brain metastases or spinal cord compression

               -  CT scan or MRI of the brain is mandatory (within 4 weeks prior to randomization)
                  in case of suspected brain metastases

               -  Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of
                  suspected spinal cord compression

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 12 weeks

          -  ANC = 1,500/mm^3

          -  Platelet count = 100,000/mm^3

          -  Hemoglobin = 9 g/dL (can be post-transfusion)

          -  INR = 1.5

          -  APTT = 1.5 times upper limit of normal (ULN)

          -  Bilirubin = 1.5 times ULN

          -  ALT and AST = 2.5 times ULN

          -  Creatinine = 2.0 mg/dL

          -  Proteinuria = 1+ by urine dipstick OR = 1 g by 24-hour urine collection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for = 6 weeks after
             completion of study therapy

          -  No significant traumatic injury within the past 4 weeks

          -  No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage
             within the past 6 months

          -  No other malignancies within the past 5 years except for adequately treated carcinoma
             in situ of the cervix, and/or basal cell skin cancer, and/or early endometrial
             carcinoma

          -  No pre-existing sensory or motor neuropathy = grade 2

          -  No history or evidence of CNS disease (e.g., uncontrolled seizures) by neurological
             examination unless adequately treated with standard medical therapy

          -  No history or evidence of thrombotic or hemorrhagic disorders

          -  No uncontrolled hypertension (i.e., blood pressure &gt; 150/100 mm Hg despite
             antihypertensive therapy)

          -  No known hypersensitivity to bevacizumab and its excipients, chemotherapy, or
             Cremophor EL

          -  No nonhealing wound, ulcer, or bone fracture

               -  Patients with granulating incisions healing by secondary intention with no
                  evidence of facial dehiscence or infection are eligible but require three weekly
                  wound examinations

          -  No clinically significant cardiovascular disease, including any of the following:

               -  Myocardial infarction or unstable angina within the past 6 months

               -  New York Heart Association class II-IV congestive heart failure

               -  Poorly controlled cardiac arrhythmia despite medication

                    -  Rate-controlled atrial fibrillation allowed

               -  Peripheral vascular disease = grade 3 (i.e., symptomatic and interfering with
                  activities of daily living requiring repair or revision)

          -  No evidence of other disease or condition, metabolic dysfunction, physical examination
             findings, or laboratory findings that would contraindicate the use of an
             investigational drug or put the patient at high-risk for treatment-related
             complications

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since other prior surgery or open biopsy

          -  No prior systemic therapy for ovarian cancer (e.g., chemotherapy, monoclonal antibody
             therapy, tyrosine kinase inhibitor therapy, or hormonal therapy)

          -  Prior adjuvant chemotherapy allowed for other malignancies (e.g., breast or colorectal
             carcinoma) if malignancy was diagnosed over 5 years ago with no evidence of subsequent
             recurrence

          -  No prior mouse CA 125 antibody

          -  No prior radiotherapy to the abdomen or pelvis

          -  More than 10 days since prior and no concurrent chronic use of acetylsalicylic acid (&gt;
             325 mg/day)

               -  Low-dose (&lt; 325 mg/day) acetylsalicylic acid allowed

          -  More than 10 days since prior and no concurrent full-dose oral or parenteral
             anticoagulants or thrombolytic agents for therapeutic purposes

               -  Use of therapy for line patency allowed provided INR &lt; 1.5

          -  More than 30 days since prior and no other concurrent investigational agent or
             participation in another clinical trial

          -  No other concurrent systemic antitumor agents

          -  No concurrent surgery

          -  No concurrent maintenance chemotherapy or intraperitoneal chemotherapy (including
             cytotoxic chemotherapy)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1520</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Cancer Therapy Centre at Liverpool Hospital - Liverpool</hospital>
    <hospital>Prince of Wales Private Hospital - Randwick</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Sydney Cancer Centre at Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Newcastle Mater Misericordiae Hospital - Waratah</hospital>
    <hospital>Westmead Institute for Cancer Research at Westmead Hospital - Wentworthville</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Royal Adelaide Hospital Cancer Centre - Adelaide</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Royal Women's Hospital - Carlton</hospital>
    <hospital>Mercy Hospital for Women - East Melbourne</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>Murray Valley Private Hospital and Cancer Treatment Centre - Wodonga</hospital>
    <hospital>Sir Charles Gairdner Hospital - Perth - Perth</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Avignon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Colmar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Chesnay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes-Saint Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Brieuc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Cloud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bremen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Chemnitz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ebersberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Esslingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Georgsmarienhuette</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Greifswald</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kassel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lahr</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leonberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Limburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Luebeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lueneburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Minden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neunkirchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuss</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Offenbach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Paderborn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Quedlinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ravensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Siegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sigmaringen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Stuttgart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wiesbaden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Witten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wolfsburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuppertal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northern Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wales</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Medical Research Council</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different
      ways to stop the growth of tumor cells, either by killing the cells or stopping them from
      dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
      growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving
      carboplatin and paclitaxel together with bevacizumab is more effective than carboplatin and
      paclitaxel alone in treating patients with ovarian epithelial cancer, fallopian tube cancer,
      or primary peritoneal cavity cancer.

      PURPOSE: This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab
      to see how well they work compared with carboplatin and paclitaxel alone in treating patients
      with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal
      cavity cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00483782</trialwebsite>
    <publication>Dhillon S. Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Drugs. 2012 May 7;72(7):917-30. doi: 10.2165/11208940-000000000-00000. Review.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tim J. Perren, MD</name>
      <address>Leeds Cancer Centre at St. James's University Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>